Saturday 17 October 2026
Export CNSY’s income statement to Excel — free account
Cerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.70
0.18
−9.57%
Follow CNSY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.17 | 5.13 | 7.61 | 13.89 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.23) | (4.26) | (6.34) | (28.67) | |
P/B ratio |
5.52 | 2.22 | 9.93 | 14.45 | |
Price to Tangible BV |
6.25 | 2.35 | 12.06 | 16.96 | |
EV/Sales |
7.67 | 3.07 | 6.80 | 12.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.45) | (0.76) | (1.71) | (4.04) | |
EV/FCF |
(1.34) | (0.71) | (1.66) | (3.90) | |
Quick Ratio |
0.48 | 2.07 | 0.74 | 1.22 | |
Current Ratio |
1.37 | 2.27 | 1.23 | 1.29 | |
Net Debt/EBITDA |
0.27 | 2.06 | 1.43 | 3.77 | |
Debt/Assets |
0.00% | 3.35% | 4.59% | 0.00% | |
Debt/Equity |
0.00 | 0.06 | 0.19 | 0.00 | |
Asset Turnover |
0.34 | 0.32 | 0.45 | 0.41 | |
Operating CF/Net income |
0.79 | 0.90 | 3.57 | 0.58 | |
Capex/Depreciation |
(3.64) | (8.52) | (0.21) | (0.44) | |
Interest Coverage |
(1,811.40) | (418.76) | — | — | |
Research and Development Expense of Revenue |
1,037.71% | 278.70% | 215.14% | 174.37% | |
Selling, General and Administrative Expense of Revenue |
1,265.94% | 513.81% | 304.90% | 246.46% | |
Intangible Assets out of Total Assets |
0.05 | 0.03 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
201.95% | 99.42% | 52.16% | 37.72% | |
Graham Net Nets |
0.11 | 0.38 | 0.07 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(76.89%) | (38.75%) | (237.25%) | (250.00%) | |
Free Cash Flow Yield |
(79.94%) | (83.79%) | (53.84%) | (22.31%) | |
Revenue per Share |
0.06 | 0.15 | 0.44 | 0.33 | |
Operating CF per Share |
(1.03) | (0.94) | (2.01) | (0.59) | |
Capex per Share |
(0.07) | (0.12) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(1.11) | (1.06) | (2.02) | (0.60) | |
Cash per Share |
0.34 | 2.27 | 2.81 | 3.86 | |
Shareholders Equity per Share |
0.79 | 1.80 | 1.28 | 1.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.79 | 1.80 | 1.28 | 1.18 | |
Free Cash Flow |
(7.63) | (7.06) | (6.29) | (2.58) | |
Working Capital |
3.20 | 10.07 | 2.86 | 3.97 | |
Capital Expenditures |
(0.50) | (0.82) | (0.03) | (0.03) | |
Net Current Asset Value |
3.20 | 10.07 | 2.84 | 3.97 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.21 | 0.80 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.17 | 0.72 | 0.52 | — | |
Average Payables |
6.95 | 7.69 | 8.60 | 9.77 | |
Average Inventory |
3.16 | — | 2.23 | — | |
Average Assets |
12.19 | 15.99 | 11.48 | 12.82 | |
Average Common Equity |
4.25 | (5.84) | (2.48) | (0.06) |
Columns are period end dates